Nonalcoholic fatty liver disease and statins

Metabolism: Clinical and Experimental

Volumn 64, Issue 10, 2015, Pages 1215-1223

  Tziomalos, Konstantinos ^a   Athyros, Vasilios G ^a   Paschos, Paschalis ^a   Karagiannis, Asterios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Cardiovascular disease; Fatty liver; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Statins

Indexed keywords

AMINOTRANSFERASE; ATORVASTATIN; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERTRANSAMINASEMIA; LIVER HISTOLOGY; MORBIDITY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; REVIEW; ANIMAL; CARDIOVASCULAR DISEASES; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; RISK FACTOR;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MORBIDITY; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS;

EID: 84941600819     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2015.07.003     Document Type: Review

References (86)

1. N. Chalasani, Z. Younossi, J.E. Lavine, A.M. Diehl, E.M. Brunt, K. Cusi, and et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association Hepatology 55 2012 2005 2023
2. J.M. Clark, F.L. Brancati, and A.M. Diehl The prevalence and etiology of elevated aminotransferase levels in the United States Am J Gastroenterol 98 2003 960 967
3. Z.M. Younossi, M. Stepanova, M. Afendy, Y. Fang, Y. Younossi, H. Mir, and et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008 Clin Gastroenterol Hepatol 9 2011 524 530
4. J.D. Browning, L.S. Szczepaniak, R. Dobbins, P. Nuremberg, J.D. Horton, J.C. Cohen, and et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity Hepatology 40 2004 1387 1395
5. C.D. Williams, J. Stengel, M.I. Asike, D.M. Torres, J. Shaw, M. Contreras, and et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study Gastroenterology 140 2011 124 131
6. C.P. Day, and O.F. James Steatohepatitis: a tale of two "hits"? Gastroenterology 114 1998 842 845
7. K. Tziomalos, V.G. Athyros, and A. Karagiannis Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options Curr Vasc Pharmacol 10 2012 162 172
8. G. Targher, L. Bertolini, R. Padovani, S. Rodella, R. Tessari, L. Zenari, and et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients Diabetes Care 30 2007 1212 1218
9. N.C. Leite, G.F. Salles, A.L. Araujo, C.A. Villela-Nogueira, and C.R. Cardoso Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus Liver Int 29 2009 113 119
10. V.G. Athyros, O. Giouleme, E.S. Ganotakis, M. Elisaf, K. Tziomalos, T. Vassiliadis, and et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study Arch Med Sci 7 2011 796 805
11. L.A. Adams, J.F. Lymp, J. St Sauver, S.O. Sanderson, K.D. Lindor, A. Feldstein, and et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study Gastroenterology 129 2005 113 121
12. M. Ekstedt, L.E. Franzén, U.L. Mathiesen, L. Thorelius, M. Holmqvist, G. Bodemar, and et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes Hepatology 44 2006 865 873
13. G. Targher, L. Bertolini, S. Rodella, R. Tessari, L. Zenari, G. Lippi, and et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients Diabetes Care 30 2007 2119 2121
14. X. Liu, O.P. Hamnvik, J.P. Chamberland, M. Petrou, H. Gong, C.A. Christophi, and et al. Circulating alanine transaminase (ALT) and γ-glutamyl transferase (GGT), but not fetuin-A, are associated with metabolic risk factors, at baseline and at two-year follow-up: the prospective Cyprus Metabolism Study Metabolism 63 2014 773 782
15. V. Messier, A.D. Karelis, M.E. Robillard, P. Bellefeuille, M. Brochu, J.M. Lavoie, and et al. Metabolically healthy but obese individuals: relationship with hepatic enzymes Metabolism 59 2010 20 24
16. B. Vozarova, N. Stefan, R.S. Lindsay, A. Saremi, R.E. Pratley, C. Bogardus, and et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes Diabetes 51 2002 1889 1895
17. A.J. Hanley, K. Williams, A. Festa, L.E. Wagenknecht, R.B. D'Agostino, J. Kempf, and et al. insulin resistance atherosclerosis study. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study Diabetes 53 2004 2623 2632
18. M. Monami, G. Bardini, C. Lamanna, L. Pala, B. Cresci, P. Francesconi, and et al. Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study Metabolism 57 2008 387 392
19. R.K. Schindhelm, J.M. Dekker, G. Nijpels, L.M. Bouter, C.D. Stehouwer, R.J. Heine, and et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study Atherosclerosis 191 2007 391 396
20. K.E. Yun, C.Y. Shin, Y.S. Yoon, and H.S. Park Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans Atherosclerosis 205 2009 533 537
21. C. Thoma, C.P. Day, and M.I. Trenell Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review J Hepatol 56 2012 255 266
22. A.J. Sanyal, N. Chalasani, K.V. Kowdley, A. McCullough, A.M. Diehl, N.M. Bass, and et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N Engl J Med 362 2010 1675 1685
23. J.A. Dormandy, B. Charbonnel, D.J. Eckland, E. Erdmann, M. Massi-Benedetti, I.K. Moules, and et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial Lancet 366 2005 1279 1289
24. Z.N. Zhu, Y.F. Jiang, and T. Ding Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials Bone 68 2014 115 123
25. R.M. Turner, C.S. Kwok, C. Chen-Turner, C.A. Maduakor, S. Singh, and Y.K. Loke Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis Br J Clin Pharmacol 78 2014 258 273
26. E.A. Klein, I.M. Thompson, C.M. Tangen, J.J. Crowley, M.S. Lucia, P.J. Goodman, and et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) JAMA 306 2011 1549 1556
27. G. Bjelakovic, D. Nikolova, L.L. Gluud, R.G. Simonetti, and C. Gluud Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis JAMA 297 2007 842 857
28. Prospective Studies Collaboration S. Lewington, G. Whitlock, R. Clarke, P. Sherliker, J. Emberson, and et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths Lancet 370 2007 1829 1839
29. Cholesterol Treatment Trialists' (CTT) Collaboration C. Baigent, L. Blackwell, J. Emberson, L.E. Holland, C. Reith, and et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
30. European Association for Cardiovascular Prevention & Rehabilitation Z. Reiner, A.L. Catapano, G. De Backer, I. Graham, M.R. Taskinen, and et al. ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 32 2011 1769 1818
31. N.J. Stone, J.G. Robinson, A.H. Lichtenstein, C.N. Bairey Merz, C.B. Blum, R.H. Eckel, and et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 129 2014 S1 S45
32. M.H. Davidson, and J.G. Robinson Safety of aggressive lipid management J Am Coll Cardiol 49 2007 1753 1762
33. F.S. Rzouq, M.L. Volk, H.H. Hatoum, S.K. Talluri, R.R. Mummadi, and G.K. Sood Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians Am J Med Sci 340 2010 89 93
34. V.G. Athyros, K. Tziomalos, T.D. Gossios, T. Griva, P. Anagnostis, K. Kargiotis, and et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis Lancet 376 2010 1916 1922
35. M.J. Tikkanen, R. Fayyad, O. Faergeman, A.G. Olsson, C.C. Wun, R. Laskey, and et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels Int J Cardiol 168 2013 3846 3852
36. N. Chalasani, H. Aljadhey, J. Kesterson, M.D. Murray, and S.D. Hall Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity Gastroenterology 126 2004 1287 1292
37. R. Vuppalanchi, E. Teal, and N. Chalasani Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes Am J Med Sci 329 2005 62 65
38. M.A. Pfeffer, A. Keech, F.M. Sacks, S.M. Cobbe, A. Tonkin, R.P. Byington, and et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project Circulation 105 2002 2341 2346
39. J.D. Browning Statins and hepatic steatosis: perspectives from the Dallas Heart Study Hepatology 44 2006 466 471
40. M. Kiyici, M. Gulten, S. Gurel, S.G. Nak, E. Dolar, G. Savci, and et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis Can J Gastroenterol 17 2003 713 718
41. L.S. Rallidis, C.K. Drakoulis, and A.S. Parasi Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study Atherosclerosis 174 2004 193 196
42. A. Hatzitolios, C. Savopoulos, G. Lazaraki, I. Sidiropoulos, P. Haritanti, A. Lefkopoulos, and et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia Indian J Gastroenterol 23 2004 131 134
43. S. Antonopoulos, S. Mikros, M. Mylonopoulou, S. Kokkoris, and G. Giannoulis Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients Atherosclerosis 184 2006 233 234
44. E. Gómez-Domínguez, J.P. Gisbert, J.A. Moreno-Monteagudo, L. García-Buey, and R. Moreno-Otero A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients Aliment Pharmacol Ther 23 2006 1643 1647
45. E.F. Georgescu, and M. Georgescu Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study J Gastrointestin Liver Dis 16 2007 39 46
46. T. Abel, J. Fehér, E. Dinya, M.G. Eldin, and A. Kovács Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease Med Sci Monit 15 2009 MS6 MS11
47. Y. Kimura, H. Hyogo, S. Yamagishi, M. Takeuchi, T. Ishitobi, Y. Nabeshima, and et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH J Gastroenterol 45 2010 750 757
48. H. Hyogo, T. Ikegami, K. Tokushige, E. Hashimoto, K. Inui, Y. Matsuzaki, and et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study Hepatol Res 41 2011 1057 1065
49. K. Kargiotis, N. Katsiki, V.G. Athyros, O. Giouleme, K. Patsiaoura, E. Katsiki, and et al. Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report Curr Vasc Pharmacol 12 2014 505 511
50. V.G. Athyros, D.P. Mikhailidis, T.P. Didangelos, O.I. Giouleme, E.N. Liberopoulos, A. Karagiannis, and et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study Curr Med Res Opin 22 2006 873 883
51. J.H. Lewis, M.E. Mortensen, S. Zweig, M.J. Fusco, J.R. Medoff, R. Belder, and et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial Hepatology 46 2007 1453 1463
52. K.H. Han, S.W. Rha, H.J. Kang, J.W. Bae, B.J. Choi, S.Y. Choi, and et al. Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage) J Clin Lipidol 6 2012 340 351
53. A. Nelson, D.M. Torres, A.E. Morgan, C. Fincke, and S.A. Harrison A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial J Clin Gastroenterol 43 2009 990 994
54. H. Bays, D.E. Cohen, N. Chalasani, and S.A. Harrison The National Lipid Association's Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update J Clin Lipidol 8 2014 S47 S57
55. N. Sattar, D. Preiss, H.M. Murray, P. Welsh, B.M. Buckley, A.J. de Craen, and et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
56. D. Preiss, S.R. Seshasai, P. Welsh, S.A. Murphy, J.E. Ho, D.D. Waters, and et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
57. M. Brault, J. Ray, Y.H. Gomez, C.S. Mantzoros, and S.S. Daskalopoulou Statin treatment and new-onset diabetes: a review of proposed mechanisms Metabolism 63 2014 735 745
58. Y. Cho, E. Choe, Y.H. Lee, J.W. Seo, Y. Choi, Y. Yun, and et al. Risk of diabetes in patients treated with HMG-CoA reductase inhibitors Metabolism 64 2015 482 488
59. P.M. Ridker, A. Pradhan, J.G. MacFadyen, P. Libby, and R.J. Glynn Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial Lancet 380 2012 565 571
60. E.S. Stroes, P.D. Thompson, A. Corsini, G.D. Vladutiu, F.J. Raal, K.K. Ray, and et al. European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management Eur Heart J 36 2015 1012 1022
61. P.M. Coen, M.G. Flynn, M.M. Markofski, B.D. Pence, and R.E. Hannemann Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage Metabolism 58 2009 1030 1038
62. G.F. Fletcher, G. Balady, S.N. Blair, J. Blumenthal, C. Caspersen, B. Chaitman, and et al. Statement on exercise: benefits and recommendations for physical activity programs for all Americans. A statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association Circulation 94 1996 857 862
63. S.E. Keating, D.A. Hackett, J. George, and N.A. Johnson Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis J Hepatol 57 2012 157 166
64. M. Yoneda, K. Fujita, Y. Nozaki, H. Endo, H. Takahashi, K. Hosono, and et al. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study Hepatol Res 40 2010 566 573
65. H. Park, T. Shima, K. Yamaguchi, H. Mitsuyoshi, M. Minami, K. Yasui, and et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease J Gastroenterol 46 2011 101 107
66. Y. Takeshita, T. Takamura, M. Honda, Y. Kita, Y. Zen, K. Kato, and et al. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial Diabetologia 57 2014 878 890
67. T.A. Le, J. Chen, C. Changchien, M.R. Peterson, Y. Kono, H. Patton, and et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial Hepatology 56 2012 922 932
68. C.K. Argo, P. Loria, S.H. Caldwell, and A. Lonardo Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 48 2008 662 669
69. V.G. Athyros, K. Tziomalos, G.N. Daskalopoulos, A. Karagiannis, and D.P. Mikhailidis Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? Ann Med 43 2011 167 171
70. V.G. Athyros, A.I. Kakafika, K. Tziomalos, A. Karagiannis, and D.P. Mikhailidis Pleiotropic effects of statins - clinical evidence Curr Pharm Des 15 2009 479 489
71. K. Tziomalos Lipid-lowering agents in the management of nonalcoholic fatty liver disease World J Hepatol 6 2014 738 744
72. W. Wang, C. Zhao, J. Zhou, Z. Zhen, Y. Wang, and C. Shen Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis PLoS One 8 2013 e76538
73. D.M. Van Rooyen, L.T. Gan, M.M. Yeh, W.G. Haigh, C.Z. Larter, G. Ioannou, and et al. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome J Hepatol 59 2013 144 152
74. Y. Okada, K. Yamaguchi, T. Nakajima, T. Nishikawa, M. Jo, Y. Mitsumoto, and et al. Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats Liver Int 33 2013 301 311
75. M. Ekstedt, L.E. Franzén, U.L. Mathiesen, M. Holmqvist, G. Bodemar, and S. Kechagias Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study J Hepatol 47 2007 135 141
76. T. Nakahara, H. Hyogo, Y. Kimura, T. Ishitobi, K. Arihiro, H. Aikata, and et al. Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study Hepatol Res 42 2012 1065 1072
77. L.M. Mangravite, M.W. Medina, J. Cui, S. Pressman, J.D. Smith, M.J. Rieder, and et al. Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin Arterioscler Thromb Vasc Biol 30 2010 1485 1492
78. M.J. Barber, L.M. Mangravite, C.L. Hyde, D.I. Chasman, J.D. Smith, C.A. McCarty, and et al. Genome-wide association of lipid-lowering response to statins in combined study populations PLoS One 5 2010 e9763
79. I. Postmus, S. Trompet, H.A. Deshmukh, M.R. Barnes, X. Li, H.R. Warren, and et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins Nat Commun 5 2014 5068
80. H.B. El-Serag, M.L. Johnson, C. Hachem, and R.O. Morgana Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes Gastroenterology 136 2009 1601 1608
81. S. Singh, P.P. Singh, A.G. Singh, M.H. Murad, and W. Sanchez Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis Gastroenterology 144 2013 323 332
82. D. Pradelli, D. Soranna, L. Scotti, A. Zambon, A. Catapano, G. Mancia, and et al. Statins and primary liver cancer: a meta-analysis of observational studies Eur J Cancer Prev 22 2013 229 234
83. M.F. Demierre, P.D. Higgins, S.B. Gruber, E. Hawk, and S.M. Lippman Statins and cancer prevention Nat Rev Cancer 5 2005 930 942
84. G. Baffy, E.M. Brunt, and S.H. Caldwell Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace J Hepatol 56 2012 1384 1391
85. J.P. Higgins, D.G. Altman, J.A. Sterne, Cochrane Statistical Methods Group, and Cochrane Bias Methods Group Chapter 8: assessing risk of bias in included studies Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 2011 The Cochrane Collaboration
86. J.J. Deeks, J.P. Higgins, D.G. Altman, and Cochrane Statistical Methods Group Chapter 9.5.2: identifying and measuring heterogeneity Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 2011 The Cochrane Collaboration